Showing results (91-100 of 969) with videos related to
Sort By:
Pageof 97
Blood|September 24, 2024
How I treat patients with AML using azacitidine and venetoclaxAndrew H Wei, Sun Loo, Naval DaverCancer Journal (Sudbury, Mass.)|January 24, 2022
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid LeukemiaFadi Haddad, Amer M Zeidan, Naval DaverCancer|June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapySangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.Pharmacological Reviews|September 25, 2016
Targeting Immune Checkpoints in Hematologic MalignanciesGheath Alatrash, Naval Daver, Elizabeth A MittendorfClinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapyNaval Daver, Theresa Liu Dumlao, Farhad Ravandi, et al.American Journal of Hematology|February 12, 2022
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemiaJayastu Senapati, Mahran Shoukier, Guillermo Garcia-Manero, et al.Future Oncology (London, England)|April 21, 2012
Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trialMichael S Mathisen, Farhad RavandiBritish Journal of Haematology|February 2, 2017
How I manage patients with hairy cell leukaemiaPhilip A Thompson, Farhad RavandiJournal of the National Comprehensive Cancer Network : JNCCN|August 11, 2012
Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?Farhad Ravandi, Jeffrey L JorgensenClinical Advances in Hematology & Oncology : H&O|December 5, 2017
A mind map for managing minimal residual disease in acute myeloid leukemiaChristopher B Benton, Farhad RavandiPageof 97